Suspending methotrexate for 2 weeks after COVID-19 vaccination

Suspending methotrexate for 2 weeks after COVID-19 vaccination

Bibliografiset tiedot
Päätekijät:	Coates, LC, Abhishek, A
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Elsevier 2022

Samankaltaisia teoksia

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Tekijä: Abhishek, A, et al.
Julkaistu: (2022)

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Tekijä: Abhishek Abhishek, et al.
Julkaistu: (2022-05-01)

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Tekijä: Abhishek, A, et al.
Julkaistu: (2023)

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Tekijä: Abhishek, A, et al.
Julkaistu: (2023)

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Tekijä: Abhishek, A, et al.
Julkaistu: (2022)

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Tekijä: Abhishek, A, et al.
Julkaistu: (2022)

Lichen planus pemphigoides erupting after COVID‐19 vaccination and infection, successfully treated with methotrexate
Tekijä: Josefin Andrén, et al.
Julkaistu: (2024-06-01)

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination
Tekijä: Robert Biesen, et al.
Julkaistu: (2022-10-01)

mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination
Tekijä: Jacqueline K. Shaia, et al.
Julkaistu: (2024-10-01)

Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination
Tekijä: Jing-Xing Li, et al.
Julkaistu: (2024-10-01)

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
Tekijä: Eugen Feist, et al.
Julkaistu: (2024-12-01)

Efficacy and tolerability of methotrexate at a dose of 15 mg/week and 10 mg/week in patients with pulmonary sarcoidosis
Tekijä: V.K. Gavrysyuk, et al.
Julkaistu: (2021-12-01)

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
Tekijä: Claudius Speer, et al.
Julkaistu: (2021-10-01)

Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation
Tekijä: E. V. Udachkina, et al.
Julkaistu: (2015-11-01)

Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation
Tekijä: E. V. Udachkina, et al.
Julkaistu: (2015-11-01)

Methotrexate in psoriasis and psoriatic arthritis
Tekijä: Coates, L, et al.
Julkaistu: (2020)

Cutaneous Eruption after SARS-CoV-2 vaccine in psoriatic patient treated with methotrexate
Tekijä: Lembo Serena, et al.
Julkaistu: (2022-01-01)

Should we stop methotrexate or not for vaccination?
Tekijä: Patrick Durez, et al.
Julkaistu: (2023-04-01)

Time Course of Antispike Antibody Titer after Administration of BNT162b2 mRNA COVID-19 Vaccine in a Patient with Rheumatoid Arthritis on Methotrexate
Tekijä: Satoshi Shinohara, et al.
Julkaistu: (2023-01-01)

Comparison of Two Therapeutic Regimens: Methotrexate-Folinic Acid (8 days) and Weekly Methotrexate in Patients with Low risk Gestational Trophoblastic neoplasia
Tekijä: zahra honarvar, et al.
Julkaistu: (2018-11-01)

Caring for the caregiver during COVID-19 suspended visitation
Tekijä: Melissa Rouse, et al.
Julkaistu: (2022-08-01)

Author Correction: Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination
Tekijä: Jing-Xing Li, et al.
Julkaistu: (2024-11-01)

UMP suspends academic operations a week starting 22 December 2021
Tekijä: Mimi Rabita, Abdul Wahit
Julkaistu: (2021)

Should methotrexate have any place in the treatment of psoriatic arthritis?
Tekijä: Ye, W, et al.
Julkaistu: (2019)

The impact of COVID-19 on care of early inflammatory arthritis in the UK
Tekijä: MacPhie, E, et al.
Julkaistu: (2022)

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
Tekijä: Henriëtte M. Y. de Jong, et al.
Julkaistu: (2019-09-01)

Methotrexate and immunogenicity of vaccines in patients with rheumatic diseases
Tekijä: В. S. Belov, et al.
Julkaistu: (2024-04-01)

Weekly methotrexate may reduce valproate levels causing relapse of genetic generalized epilepsy
Tekijä: Ajith Cherian, et al.
Julkaistu: (2021-01-01)

Deaths among young people in England increased significantly in 10 of 11 weeks after COVID-19 vaccination and doubled in three
Tekijä: Jarle Aarstad
Julkaistu: (2024-07-01)

Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination
Tekijä: Samuel D. Stampfer, et al.
Julkaistu: (2022-01-01)

Paraplegia after intrathecal administration of methotrexate
Tekijä: L Ulukutlu, et al.
Julkaistu: (1983-07-01)

Ascending myelopathy after intrathecal methotrexate
Tekijä: Yi‐Hsiang Chiu, et al.
Julkaistu: (2021-11-01)

Acceptability of Healthcare Professionals to Get Vaccinated against COVID-19 Two Weeks before Initiation of National Vaccination
Tekijä: Athanasia Pataka, et al.
Julkaistu: (2021-06-01)

COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
Tekijä: Sharon L. Walmsley, et al.
Julkaistu: (2023-04-01)

Repeated daily dosing of weekly methotrexate therapy causing multiorgan toxicity: a case report
Tekijä: Emma Davey, et al.
Julkaistu: (2023-12-01)

The effectiveness of combined local and systemic methotrexate treatment in cesarean scar pregnancy weeks 8 to 14
Tekijä: Xuyen Van, et al.
Julkaistu: (2023-01-01)

A 16-week multicenter observational study of the efficiency and safety of rheumatoid arthritis therapy with methotrexate
Tekijä: R. M. Balabanova
Julkaistu: (2018-12-01)

Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study
Tekijä: Kye E Poronsky, et al.
Julkaistu: (2023-02-01)

Better to Be Unpaid than COVID-19 Vaccinated! A Qualitative Study on Italian Nurses Suspended from Work without Salary
Tekijä: Serena Picelli, et al.
Julkaistu: (2023-07-01)

Recurrence of methotrexate-induced leukoencephalopathy after methotrexate rechallenge: A case report and literature review
Tekijä: Ammar AlKawi, MD, et al.
Julkaistu: (2023-03-01)